Biosimilars in Rare and Orphan Diseases

The emergence of biosimilars in rare and orphan diseases marks a critical turning point in the accessibility and affordability of advanced biologic therapies for small and underserved patient populations. Rare diseases, defined in many regions as conditions affecting a small percentage of the population, often lack effective treatments due to limited commercial incentives and high development costs. When therapies do exist—typically in the form of biologics such as monoclonal antibodies, enzyme replacement therapies, or fusion proteins—they are frequently priced at a premium, placing a substantial burden on healthcare systems and making access difficult for patients, particularly in low- and middle-income countries. The introduction of biosimilars offers a potential solution to this challenge by increasing treatment options and lowering costs, thereby expanding access to life-altering or life-saving therapies for patients with rare conditions. Despite the enormous potential, the development and adoption of biosimilars in the context of rare diseases face unique scientific, regulatory, and market-related challenges. From a scientific perspective, rare diseases often involve highly complex biologics and a limited understanding of disease mechanisms, which makes demonstrating biosimilarity more difficult. 

    Related Conference of Biosimilars in Rare and Orphan Diseases

    September 15-16, 2025

    29th Global Congress on Biotechnology

    Paris, France
    December 04-05, 2025

    9th International Conference on Protein Engineering

    Paris, France
    December 11-12, 2025

    7th International Conference on Biochemistry

    Prague, Czech Republic
    December 22-23, 2025

    29th World Congress on Biotechnology

    Barcelona, Spain
    April 27-28, 2026

    7th Annual Congress on Biosimilars and Future Biotherapeutics

    Paris, Aland Islands

    Biosimilars in Rare and Orphan Diseases Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in